Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03744182 · ClinicalTrials.gov registry record · Phase 1
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
A Phase 1 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT03744182 is a Phase 1 study that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 66 participants.
The verdict
NCT03744182, a Phase 1 study, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD
Interventions
- DRUG HM15211
- DRUG Placebo of HM15211
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2020-03-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03744182
The ClinicalTrials.gov registry entry for NCT03744182 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HM15211 is the first listed.
NCT03744182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03744182 about?
NCT03744182 is a clinical study titled "A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD". This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD
What is the current status of trial NCT03744182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2018-11-01. Estimated completion is 2020-03-18.
What interventions are being tested in trial NCT03744182?
The interventions under investigation include: HM15211 (DRUG), Placebo of HM15211 (DRUG).
Who is sponsoring clinical trial NCT03744182?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.